22.07.2013 Views

Research and treatment timeline: 30+ years of ms milestones | 4

Research and treatment timeline: 30+ years of ms milestones | 4

Research and treatment timeline: 30+ years of ms milestones | 4

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Volume 39 • Issue 2<br />

<strong>Research</strong> <strong>and</strong><br />

<strong>treatment</strong><br />

<strong>timeline</strong>: <strong>30+</strong><br />

<strong>years</strong> <strong>of</strong> <strong>ms</strong><br />

<strong>milestones</strong> | 4<br />

3 5<br />

<strong>Research</strong> Portal:<br />

you can participate<br />

in <strong>ms</strong> research<br />

CANADA<br />

FAll/WINTeR 2012<br />

special feature:<br />

spotlight on<br />

research<br />

<strong>ms</strong>socIeTy.cA


<strong>ms</strong> canada Fall/Winter 2012 2<br />

am <strong>of</strong>ten reminded,<br />

I during conversations<br />

with people living with<br />

multiple sclerosis,<br />

that hope for an end<br />

Yves savoie<br />

to MS can mean<br />

very different things<br />

to different people. Whether it’s hope for a<br />

cure or hope for more effective symptom<br />

management, we are hopeful that advances<br />

in research will one day <strong>of</strong>fer a means to an<br />

end to MS. This issue <strong>of</strong> MS Canada focuses<br />

on research, past <strong>and</strong> present. Through<br />

increasing our knowledge about multiple<br />

sclerosis we are hopeful that a future free <strong>of</strong><br />

this disease can exist.<br />

We welcome the federal government’s<br />

announcement that the Phase I/II clinical trial<br />

for chronic cerebrospinal venous insufficiency<br />

(CCSVI) has received the necessary medical<br />

<strong>and</strong> ethical approvals required to proceed.<br />

The national MS interventional clinical trial<br />

is a collaborative initiative between the<br />

Government <strong>of</strong> Canada, provinces where there<br />

are trial sites <strong>and</strong> the MS Society. We are<br />

hopeful that the research <strong>of</strong> Dr. Traboulsee<br />

<strong>and</strong> his collaborators will provide significant<br />

insights to those living with MS <strong>and</strong> provide<br />

answers on questions about CCSVI <strong>and</strong> MS.<br />

My sincerest thanks to those who provided<br />

feedback on the Renewal Initiative, a 12-month<br />

process <strong>of</strong> engagement that sought ways for<br />

Ms Canada, Fall/Winter 2012<br />

Published by the Multiple Sclerosis Society <strong>of</strong> Canada<br />

175 Bloor St. E., Suite 700, Toronto ON M4W 3R8<br />

Tel: (416) 922-6065 • Fax: (416) 922-7538<br />

Toll free: 1-866-922-6065 • Website: <strong>ms</strong>society.ca/<strong>ms</strong>canada<br />

Charitable Registration no. 10774 6174 RR0001<br />

Our Mission: To be a leader in finding a cure for multiple sclerosis<br />

<strong>and</strong> enabling people affected by MS to enhance their quality <strong>of</strong> life.<br />

President <strong>and</strong> chief executive <strong>of</strong>ficer: Yves Savoie<br />

Editor-in-chief: Tiffany Regaudie<br />

Managing editor: Krysta Celestine<br />

ISSN 0315-1131<br />

Canadian Publications Mail Product<br />

Sales Agreement No. 40063383<br />

Message from yves<br />

the MS Society to be more effective <strong>and</strong><br />

efficient in delivering upon its mission. To those<br />

who provided input during this process, please<br />

know that you have played a significant role<br />

in helping to ensure that we will continue to<br />

best serve those affected by MS. For up to date<br />

information on the Renewal Initiative please<br />

visit <strong>ms</strong>society.ca/renewal<br />

I am also pleased to announce the<br />

appointment <strong>of</strong> Owen Charters to the<br />

position <strong>of</strong> chief development <strong>of</strong>ficer (CDO)<br />

effective January 14, 2013. Owen has played<br />

significant leadership roles spanning from<br />

hospital foundations to member-based,<br />

multi-level national organizations. Owen<br />

served CanadaHelps as president <strong>and</strong> chief<br />

executive <strong>of</strong>ficer since 2007 <strong>and</strong> is currently<br />

adjunct faculty at the Schulich School <strong>of</strong><br />

Business at York University. Owen will provide<br />

strategic vision <strong>and</strong> dynamic leadership as<br />

the architect <strong>of</strong> the MS Society’s development<br />

<strong>and</strong> marketing progra<strong>ms</strong>.<br />

A note <strong>of</strong> recognition <strong>and</strong> gratitude is also<br />

extended to Genzyme, a San<strong>of</strong>i Company,<br />

for their support <strong>of</strong> this edition <strong>of</strong> MS Canada<br />

through an unrestricted educational grant. I<br />

have heard from people living with MS that<br />

research brings them hope. I share in this<br />

sentiment <strong>and</strong> hope that the future will also<br />

bring answers <strong>and</strong> a cure. ■<br />

Yves Savoie<br />

Attention! We would like to keep in touch<br />

via email. If you would like to receive future<br />

issues <strong>of</strong> MS Canada electronically instead<br />

<strong>of</strong> a printed version, please send your full<br />

name, current address <strong>and</strong> email address to<br />

<strong>ms</strong>canada@<strong>ms</strong>society.ca<br />

ON THE COVER: Dr. Jiwon Oh, winner <strong>of</strong><br />

the Decker Family endMS <strong>Research</strong> <strong>and</strong> Training<br />

Network Transitional Career Development Award


Friendly Visiting Volunteer Program:<br />

Companionship for long-term care residents<br />

Clare, a former nurse with secondaryprogressive<br />

MS, has lived in long-term<br />

care for 12 <strong>years</strong>. While she is fortunate to<br />

have many friends <strong>and</strong> family who visit her,<br />

Clare is especially grateful for her friendship<br />

with Robin, her visitor from the MS Society’s<br />

Friendly Visiting Volunteer Program.<br />

“Robin <strong>and</strong> I are so much alike,” Clare says.<br />

“We hit it <strong>of</strong>f right away.” Robin, who was<br />

diagnosed with MS three <strong>years</strong> ago, visits her<br />

every Thursday. “We just sit <strong>and</strong> share things,”<br />

Clare says. “We go to the farmer’s market in<br />

the morning when it’s a little cooler <strong>and</strong> when<br />

we’re at a better energy level.”<br />

A study led by Dr. Sharon Warren <strong>of</strong> the<br />

University <strong>of</strong> Alberta 1 found that people with<br />

MS who live in long-term care are <strong>of</strong>ten<br />

isolated, lonely <strong>and</strong> at risk <strong>of</strong> depression. In<br />

2008, the MS Society, Alberta <strong>and</strong> Northwest<br />

Territories Division successfully advocated for<br />

provincial government funding for the Friendly<br />

Visiting Volunteer Program, which matches<br />

Anne was diagnosed with multiple sclerosis<br />

in April 2012, but she <strong>and</strong> her doctor<br />

believe she has had the disease for more<br />

than 20 <strong>years</strong>. “I’ve experienced a lot <strong>of</strong><br />

small, mysterious sympto<strong>ms</strong> throughout my<br />

life,” Anne says. “When I was finally able to<br />

put a name to the disease, I tried to find out<br />

everything I could about it.”<br />

When Anne accessed the MS Society website,<br />

she discovered the new MS <strong>Research</strong> Portal;<br />

as a former nurse, Anne sees the value <strong>of</strong><br />

participating in medical research. To start,<br />

Anne took part in Dr. Michelle Ploughman’s<br />

extensive “Canadian Survey <strong>of</strong> Health<br />

Lifestyle <strong>and</strong> Aging with MS,” which gathers<br />

information on mental health, physical health,<br />

volunteers with people with MS who would<br />

benefit from companionship.<br />

The program currently operates in Edmonton<br />

<strong>and</strong> Calgary, where over 100 residents receive<br />

visits from volunteers <strong>and</strong> staff who run the<br />

program. The MS Society is working closely<br />

with the Alberta government to exp<strong>and</strong> the<br />

program to rural Alberta.<br />

Clare feels that Robin has become much more<br />

than a visitor. The two share a very warm<br />

friendship, <strong>and</strong> every week that they are<br />

together, they provide each other with moral<br />

support. The visits also give her a sense <strong>of</strong><br />

satisfaction. “I’m not nursing physically, but<br />

I’m nursing on a psychological <strong>and</strong> spiritual<br />

level,” Clare says.<br />

For more information, visit <strong>ms</strong>society.ca/<br />

friendlyvisiting ■<br />

1 Warren, S. et al. A pr<strong>of</strong>ile <strong>of</strong> multiple sclerosis patients in long term<br />

care centres using the Continuing Care Needs Determination Instrument<br />

(CCNDI). Presented at the Consortium <strong>of</strong> Multiple Sclerosis Centres<br />

Conference, Halifax, Nova Scotia, 2000.<br />

MS <strong>Research</strong> Portal: you can participate in <strong>ms</strong> research<br />

diet, exercise, smoking, stress <strong>and</strong> other<br />

aspects <strong>of</strong> health in relation to the trajectory<br />

<strong>of</strong> MS in one’s life.<br />

The MS <strong>Research</strong> Portal website features<br />

research studies in Canada that are<br />

currently seeking participants. All studies<br />

are supported by the MS Society or other<br />

recognized funding agencies that have formal<br />

peer review processes.<br />

“Participating in research isn’t just for me,”<br />

Anne says. “The information I provide is going<br />

to help someone else with MS looking to<br />

educate the<strong>ms</strong>elves on the disease.”<br />

To access the MS <strong>Research</strong> Portal, visit<br />

<strong>ms</strong>research.ca ■<br />

<strong>ms</strong> canada Fall/Winter 2012 3


<strong>ms</strong> canada Fall/Winter 2012 4<br />

<strong>Research</strong> <strong>and</strong> <strong>treatment</strong> <strong>timeline</strong>: <strong>30+</strong> <strong>years</strong> <strong>of</strong> MS <strong>milestones</strong><br />

While there is still a long way to go in underst<strong>and</strong>ing multiple sclerosis <strong>and</strong> finding a cure, we<br />

are pleased to look back on the important advancements that have been made to broaden our<br />

underst<strong>and</strong>ing <strong>of</strong> this complex disease <strong>and</strong> improve quality <strong>of</strong> life.<br />

For complete information on MS Society funded research, visit <strong>ms</strong>society.ca/researchsummaries<br />

For a more detailed version <strong>of</strong> the MS research <strong>timeline</strong>, please visit <strong>ms</strong>society.ca/research<strong>timeline</strong><br />

Magnetic resonance imaging (MRI) first<br />

used to examine a person with MS<br />

Canadian researchers find gene<br />

linkage to MS susceptibility<br />

Rebif ® <strong>and</strong> Avonex ® (interferon<br />

beta-1a) approved in Canada for<br />

relapsing-remitting MS to reduce the<br />

number <strong>of</strong> attacks, slow the progression<br />

<strong>of</strong> physical disability <strong>and</strong> to reduce the<br />

number <strong>of</strong> brain lesions seen on MRI<br />

MSSRF funds study <strong>of</strong> $4 million over<br />

six <strong>years</strong> that ai<strong>ms</strong> to determine whether<br />

transplanting bone marrow stem cells in<br />

people with MS can stop the disease<br />

Link between vitamin D <strong>and</strong> the reduced<br />

risk <strong>of</strong> MS identified<br />

Dr. Paolo Zamboni identifies a<br />

possible association between chronic<br />

cerebrospinal venous insufficiency<br />

(CCSVI) <strong>and</strong> MS<br />

MS Society <strong>and</strong> the National MS Society<br />

(USA) commit over $2.4 million to support<br />

seven new research projects focusing on<br />

CCSVI <strong>and</strong> its relationship to MS<br />

MSSRF funds a $3.8 million study on<br />

progressive for<strong>ms</strong> <strong>of</strong> MS<br />

1981<br />

1996<br />

1998<br />

2000<br />

2004<br />

2008<br />

2010<br />

2011<br />

1995<br />

1997<br />

1999<br />

2004<br />

2006<br />

2009<br />

2011<br />

2011<br />

Betaseron ® (interferon beta-1b) approved<br />

by Health Canada for <strong>treatment</strong> <strong>of</strong> people<br />

with relapsing-remitting MS<br />

Copaxone ® (glatiramer acetate) approved<br />

in Canada for people with RRMS who are<br />

able to walk to reduce frequency <strong>of</strong> attacks<br />

Multiple Sclerosis Scientific <strong>Research</strong><br />

Foundation (MSSRF) funds Canadian<br />

Collaborative Project on Genetic<br />

Susceptibility in MS, in the amount <strong>of</strong><br />

$4.7 million over three <strong>years</strong><br />

Betaseron ® (interferon beta-1b) approved<br />

by Health Canada as a <strong>treatment</strong> for<br />

secondary-progressive MS, to slow the<br />

progression <strong>of</strong> disability <strong>and</strong> to reduce the<br />

frequency <strong>of</strong> MS attacks<br />

MSSRF funds a five-year, $4.3 million<br />

study on children who experience an initial<br />

attack <strong>of</strong> MS <strong>and</strong> who go on to experience<br />

a second, in hope <strong>of</strong> identifying key triggers<br />

which cause MS<br />

Tysabri ® (natalizumab) approved for<br />

<strong>treatment</strong> <strong>of</strong> RRMS to reduce the frequency<br />

<strong>of</strong> relapses, delay the progression <strong>of</strong><br />

disability <strong>and</strong> reduce the number <strong>and</strong><br />

volume <strong>of</strong> brain lesions seen on MRI<br />

Extavia ® (interferon beta-1b) approved in<br />

Canada for reduction <strong>of</strong> relapses in RRMS<br />

<strong>and</strong> slowing <strong>of</strong> disability in secondaryprogressive<br />

MS<br />

Gilenya ® (fingolimod), first oral diseasemodifying<br />

therapy for MS, approved in Canada<br />

MS Society funded study at the University<br />

<strong>of</strong> Alberta discovers new MRI method that<br />

measures iron levels in brain tissue to track<br />

disease progression


special feature: Spotlight on research<br />

Whether discovering new ways to treat sympto<strong>ms</strong> or trying to find a cure, researchers<br />

are working hard to make advances that will benefit the lives <strong>of</strong> people with MS. Through<br />

research in the areas <strong>of</strong> myelin repair, symptom management, environment as a possible<br />

cause <strong>and</strong> the development <strong>of</strong> <strong>treatment</strong>s for MS, the research <strong>of</strong> today looks to form a<br />

path to a brighter future for those who live with MS.<br />

In this special feature, we are pleased to highlight some <strong>of</strong> the important research<br />

happening right now in the MS community.<br />

myelin repair<br />

Myelin is<br />

the fatty<br />

coating that<br />

protects <strong>and</strong><br />

surrounds nerve<br />

fibres within the<br />

central nervous<br />

system. Often<br />

compared to the<br />

insulating material around electrical<br />

wiring, myelin aids the conduction <strong>of</strong><br />

electrical signals between neurons<br />

within the spinal cord <strong>and</strong> brain.<br />

Multiple sclerosis involves the body’s<br />

immune system attacking <strong>and</strong><br />

destroying myelin. Such demyelination<br />

can cause interference in transmitting<br />

nerve signals, which can cause blurred<br />

vision, slurred speech, trembling <strong>and</strong><br />

cognitive difficulties.<br />

Some approved therapies for MS<br />

involve slowing down the body’s<br />

immune system to prevent it<br />

from attacking the myelin. Such<br />

<strong>treatment</strong> can prevent the disease<br />

from progressing <strong>and</strong> can minimize<br />

attacks. <strong>Research</strong> is currently<br />

ongoing with regard to developing<br />

techniques to induce myelin repair<br />

with antibodies; however, studies<br />

are still exploring if this method can<br />

be effective in restoring the loss <strong>of</strong><br />

myelin in humans.<br />

What’s happening now<br />

Michael Keough<br />

university <strong>of</strong> Calgary<br />

PhD studentship<br />

Michael Keough is the recipient<br />

<strong>of</strong> a 2012 MS Society <strong>of</strong><br />

Canada Doctoral Award for his<br />

project, “Altering the Inhibitory<br />

Microenvironment to Promote<br />

Oligodendrocyte Maturation <strong>and</strong> Remyelination.”<br />

Remyelination is characteristic in acute multiple<br />

sclerosis (MS) lesions yet <strong>of</strong>ten fails in chronic<br />

stages <strong>of</strong> disease. Oligodendrocyte precursor cells<br />

(OPCs) reside in chronic MS lesions in immature<br />

states, suggesting that inhibitory molecules in the<br />

lesion environment cause remyelination failure.<br />

Extracellular matrix molecules called “chondroitin<br />

sulfate proteoglycans” are abnormally elevated in<br />

chronic MS lesions, <strong>and</strong> data indicates that they are<br />

responsible for remyelination failure.<br />

Mr. Keough’s goal is to further analyze these<br />

molecules <strong>and</strong> seek therapeutics to overcome<br />

their inhibition <strong>of</strong> OPCs, such that remyelination<br />

can be possible in chronic stages <strong>of</strong> MS.<br />

“There are currently no MS medications targeted to<br />

directly impact regeneration <strong>of</strong> lost myelin,” Keough<br />

says. “A new angle <strong>of</strong> <strong>treatment</strong>, in combination with<br />

current <strong>and</strong> advancing immunomodulatory therapies,<br />

may be beneficial to people living with MS.”<br />

<strong>ms</strong> canada Fall/Winter 2012 5


<strong>ms</strong> canada Fall/Winter 2012 6<br />

symptom management<br />

Sympto<strong>ms</strong> <strong>of</strong> MS include pain, fatigue, bladder dysfunction, vision proble<strong>ms</strong>, difficulty<br />

walking, cognitive change <strong>and</strong> dizziness.<br />

Managing sympto<strong>ms</strong> in MS is essential throughout the course <strong>of</strong> the disease. It is important<br />

for those who live with MS to underst<strong>and</strong> their sympto<strong>ms</strong> <strong>and</strong> seek available methods to<br />

improve quality <strong>of</strong> life. Proper symptom management involves underst<strong>and</strong>ing how MS can be<br />

treated, seeking proper care from health pr<strong>of</strong>essionals <strong>and</strong> maintaining a healthy lifestyle.<br />

What’s happening now<br />

Dr. Neil Rector<br />

sunnybrook<br />

<strong>Research</strong> Institute<br />

Dr. Neil Rector is the<br />

recipient <strong>of</strong> a 2012 MS<br />

Society Operating Grant for<br />

his project, “A R<strong>and</strong>omized<br />

Controlled Trial Testing the Additive<br />

Benefits <strong>of</strong> Cognitive Behaviour Therapy<br />

(CBT) <strong>and</strong> Exercise for Depression <strong>and</strong><br />

Cognitive Dysfunction in MS.”<br />

Dr. Rector’s goals are to investigate the<br />

effects <strong>of</strong> CBT, exercise <strong>and</strong> a combination<br />

<strong>of</strong> the two on episodes <strong>of</strong> depression <strong>and</strong><br />

neuropsychological functioning.<br />

“The results <strong>of</strong> this clinical study will<br />

provide an important contribution to<br />

knowledge about the <strong>treatment</strong> <strong>and</strong><br />

associated neurocognitive aspects <strong>of</strong><br />

depression in MS,” Dr. Rector says.<br />

“This study will be the first to determine<br />

whether evidence-based, non-medical<br />

<strong>treatment</strong>s for mood disorders in MS<br />

reduce underlying cognitive substrates<br />

associated with the illness <strong>and</strong> known to<br />

be exacerbated by depression.”<br />

“<br />

The results <strong>of</strong><br />

this clinical<br />

study will<br />

provide an<br />

important<br />

contribution to<br />

knowledge about<br />

the <strong>treatment</strong><br />

<strong>and</strong> associated<br />

neurocognitive<br />

aspects <strong>of</strong><br />

depression<br />

in MS.<br />


environment as a possible cause <strong>of</strong> MS<br />

Multiple sclerosis is more common in people who live farther from the equator (although<br />

many exceptions exist). Decreased sunlight exposure has been linked to a higher risk <strong>of</strong> MS.<br />

Decreased vitamin D production <strong>and</strong> intake is the main biological mechanism used to explain<br />

the higher risk <strong>of</strong> MS among those less exposed to sun.<br />

A three-year study coordinated by the World Health Organization (WHO) <strong>and</strong> the Multiple Sclerosis<br />

International Federation (MSIF) highlights prevalence <strong>of</strong> MS across the world. Canada has been<br />

identified as being one <strong>of</strong> the countries with the highest prevalence <strong>of</strong> MS in the world.<br />

What’s happening now<br />

Dr. Afsaneh shirani<br />

university <strong>of</strong><br />

British Columbia<br />

Afsaneh Shirani is a recipient<br />

<strong>of</strong> a 2012 MS Society<br />

Postdoctoral Fellowship.<br />

Dr. Shirani’s project<br />

entitled, “Temporal Changes in Disability<br />

Progression <strong>and</strong> Demographics in Multiple<br />

Sclerosis” will investigate if disability<br />

progression has changed over time in<br />

patients with MS in British Columbia. It will<br />

also examine whether there have been<br />

changes in sex ratio (i.e. the number <strong>of</strong><br />

men <strong>and</strong> women with MS), onset age <strong>and</strong><br />

disease course over time in patients with<br />

MS living in British Columbia, Nova Scotia<br />

<strong>and</strong> Manitoba.<br />

“The results <strong>of</strong> this project would contribute<br />

to a better underst<strong>and</strong>ing <strong>of</strong> the natural<br />

course <strong>of</strong> MS <strong>and</strong> may have important<br />

implications for the role <strong>of</strong> environmental<br />

factors in MS,” Shirani says. “This project<br />

will also provide insights for better social,<br />

economic <strong>and</strong> healthcare planning for<br />

those with MS.”<br />

“<br />

The results <strong>of</strong><br />

this project<br />

will contribute<br />

to a better<br />

underst<strong>and</strong>ing<br />

<strong>of</strong> the natural<br />

course <strong>of</strong> MS<br />

<strong>and</strong> may have<br />

important<br />

implications<br />

for the role <strong>of</strong><br />

environmental<br />

factors in MS.<br />

”<br />

<strong>ms</strong> canada Fall/Winter 2012 7


<strong>ms</strong> canada Fall/Winter 2012 8<br />

MS <strong>treatment</strong>s<br />

Thanks to research within Canada <strong>and</strong> around the world, new <strong>treatment</strong>s for multiple<br />

sclerosis are steadily emerging. Medications may decrease the severity <strong>of</strong> MS relapses caused<br />

by increased inflammation in the central nervous system, but they may also treat sympto<strong>ms</strong><br />

such as fatigue, pain <strong>and</strong> muscle tightness. These <strong>treatment</strong>s look to improve the quality <strong>of</strong><br />

life for people with MS.<br />

What’s happening now<br />

Dr. Bradley Kerr<br />

university <strong>of</strong> Alberta<br />

Dr. Bradley Kerr was awarded<br />

a 2012 Donald Paty Career<br />

Development Award for his<br />

project, “Examining the Underlying<br />

Mechanis<strong>ms</strong> <strong>of</strong> Neuropathic Pain in<br />

Multiple Sclerosis.”<br />

Chronic pain greatly impacts the quality <strong>of</strong> life for<br />

people living with MS. Neuropathic pain occurs<br />

when damage takes place within the nervous<br />

system. Currently, there are not many effective<br />

<strong>treatment</strong>s to relieve this type <strong>of</strong> pain, as little is<br />

known about what causes it.<br />

Dr. Kerr ai<strong>ms</strong> to test whether the function <strong>of</strong><br />

glutamate transporters proteins that control pain<br />

signals in the nervous system are impaired,<br />

leading to neuropathic pain. He will go on to test<br />

if a particular drug that is used to restore the<br />

function <strong>of</strong> glutamate transporter can prevent<br />

neuropathic pain. He will further investigate how<br />

a clinical <strong>treatment</strong> that reduces inflammation<br />

can affect neuropathic pain, <strong>and</strong> if it will have any<br />

effect on glutamate transporters.<br />

“My research program ai<strong>ms</strong> to identify the causes<br />

<strong>of</strong> pain in MS,” says Dr. Kerr. “This will help<br />

generate new therapies to improve the quality <strong>of</strong><br />

life for MS patients.”<br />

“<br />

My research<br />

program ai<strong>ms</strong><br />

to identify the<br />

causes <strong>of</strong><br />

pain in MS.<br />

This will help<br />

generate new<br />

therapies to<br />

improve the<br />

quality <strong>of</strong><br />

life for MS<br />

patients.<br />


canadian Physical Activity Guidelines for Adults with <strong>ms</strong><br />

he Canadian Society for Exercise<br />

T Physiology (CSEP) has released Canadian<br />

Physical Activity Guidelines for Adults with MS.<br />

The MS Society recommends these guidelines<br />

for those living with MS who want to pursue<br />

physical activity. These are the first set <strong>of</strong><br />

physical activity guidelines for adults with<br />

MS developed through a rigorous, multi-step<br />

process that meets international st<strong>and</strong>ards for<br />

guideline development.<br />

Following these guidelines can improve<br />

aerobic endurance <strong>and</strong> muscle strength<br />

among adults with minimal to moderate FOR<br />

SUMMARY OF THE<br />

disability resulting from either relapsingremitting<br />

or progressive for<strong>ms</strong> <strong>of</strong> MS. Meeting<br />

these guidelines may also reduce fatigue,<br />

improve mobility <strong>and</strong> enhance elements <strong>of</strong><br />

health-related quality <strong>of</strong> life.<br />

Currently, there is no scientific evidence<br />

that following these guidelines will result in<br />

relapse <strong>of</strong> MS sympto<strong>ms</strong> or worsen fatigue<br />

or health related quality <strong>of</strong> life. A summary<br />

<strong>of</strong> the guidelines is provided below.<br />

To view the full guidelines <strong>and</strong> for more<br />

2012 SCIENTIFIC STATEMENTS<br />

information, visit csep.ca/guidelines or<br />

<strong>ms</strong>society.ca/physicalguidelines ■<br />

Canadian Physical Activity Guidelines<br />

FOR ADULTS WITH MULTIPLE SCLEROSIS<br />

24<br />

24<br />

24<br />

Guidelines<br />

To achieve important fitness benefits, adults aged 18-65 <strong>years</strong> with multiple<br />

sclerosis who sum have audaeseque mild to nonsequ moderate aspidit et disability que natae cuptatqui need rent at doluptum least: voloribus rerersp elictum ut<br />

et l<strong>and</strong>em qui cusapic ipient audaerestint exerecae labo. On cum voluptatus <strong>and</strong>i doloria spienda nam<br />

• 30 minutes eos <strong>of</strong> mos moderate doloriam fugias intensity debit, occullenim aerobic autas plis activity, etur aut plabores 2 times et omnime per week, occulparci utatest<br />

AND<br />

accaboresti culluptiisci re, sequiatur? Ximin num id que voleces dolupta estrumet aruntisciam reratur as<br />

• Strength training exercises for major muscle group, 2 times per week.<br />

Meeting these guidelines may also reduce fatigue, improve mobility <strong>and</strong> enhance<br />

elements <strong>of</strong> health related to quality <strong>of</strong> life.<br />

Let’s talk intensity!<br />

Canadian Physical Activity Guidelines<br />

Preamble<br />

Aximus inveriore, qui acium sunt.<br />

Is etus eius es apisqua temquam as rem eatqui consenisin prate exceperum audae dolla nihillupist,<br />

tempeliquo earcide rferchic tem aria cus dolorita qui te voluptati autatus daniasperum qui rehendu<br />

cipsaessed ut et volupta tiosam voles quostem corio inciliquodis modiscieniet quide dolo omnis asperem<br />

faceper spitisit, quiat.<br />

Magnis ipsaectes autem inim intius ducipsaped mo id ut quod es et essint.<br />

Officidelit hilitasim quunt omnim vidit, aboreium verum sequame nis dolore, con el is eum ne lam sintio<br />

evenihici sincto maionsed quiatemque aut et eosaper chillaut dempori busdae. Nem. Es enis siti<strong>and</strong>am<br />

abor sunt est, a natibusam con cus sam, non con et <strong>of</strong>fic tem rent accum volent res aliqui dolectemqui sit<br />

et volores accus eos molorae volupta sperorent expedisse nihitat uritat lacil ea dolorestem que natempe<br />

rnatem faciatur molorio reprectori non prae vollictor aborepe rorionsento doluptas ut reium et volupta<br />

quuntur?<br />

Dellupt atiam, optatur arum ide natusaes quodis aut mos enda doluptia vit, sam illaborem harcili tatibus<br />

ipsam quam aut et harcipsam elestis estiure cumqui <strong>of</strong>ficim pernatur, sit, acerumq uaeremporum venditis<br />

seque nem fuga. Nam rerovitaque nam quae quas ellauta voluptat voluptatia siminctecus volum volende<br />

licienest, el id quo et qui odi con erferios sam eturepe digendel ium resed minventuria doluptatur min ent<br />

vitateces moluptatibus autemqui ommo test experfe ristrum nostiuntiore pori<strong>and</strong>it quatis dis as ime nobis<br />

sus as rem fuga. Mus sitiorro essinti dit, ilit pl<strong>and</strong>e nonsequodio te volupta ssequo mod mostion sedipita<br />

Guidelines<br />

• Moderate-intensity physical activity<br />

is usually a 5 or 6 on a scale <strong>of</strong> 10<br />

<strong>and</strong> causes your heart rate to go up<br />

• Pick a resistance (free weights, cable<br />

pulleys, b<strong>and</strong>s, etc.) heavy enough<br />

that you can barely, but safely, finish<br />

10-15 repetitions <strong>of</strong> the last set<br />

• Repetitions are the number <strong>of</strong> times<br />

you lift <strong>and</strong> lower a weight<br />

Important things to know<br />

• Rum quae vendi dolorep erferuptate eturem que am, tore volendae nulpa<br />

volori sus at ent ullupti quamus, velitis earit expelecus.<br />

• Aerobic <strong>and</strong> strength training<br />

activities can be done on the<br />

same day<br />

• Rest your muscles for at least one<br />

day between strength training<br />

sessions<br />

o Hicitate molore dio cuptatibea consequi doluptate iust, issi im<br />

o Hicitate molore dio cuptatibea consequi doluptate iust, issi im.<br />

• Hicitate molore dio cuptatibea consequi doluptate iust, issi im<br />

© Canadian Society for Exercise Physiology, 2012. All rights reserved.<br />

For more information<br />

please go to …<br />

www.csep.ca/guidelines<br />

<strong>ms</strong> canada Fall/Winter 2012 9


<strong>ms</strong> canada Fall/Winter 2012 10<br />

<strong>Research</strong> is hope: The Decker family<br />

Bob <strong>and</strong> Pat Decker with Dr. Jiwon Oh<br />

Dr. Jiwon oh,<br />

winner <strong>of</strong> the Decker<br />

Family endMS<br />

<strong>Research</strong> <strong>and</strong><br />

Training Network<br />

Transitional Career<br />

Development Award<br />

When Bob Decker’s wife, Pat, was<br />

diagnosed with relapsing-remitting<br />

multiple sclerosis in 1989, he took action<br />

by raising almost $10,000 for his local MS<br />

Walk. Over 20 <strong>years</strong> later, Bob remains an<br />

active member <strong>of</strong> the MS Society – <strong>and</strong> his<br />

generous gift <strong>of</strong> $500,000 to the endMS<br />

campaign will fund the Decker Family endMS<br />

<strong>Research</strong> <strong>and</strong> Training Network Transitional<br />

Career Development Award for a young<br />

postdoctoral fellow.<br />

For Bob <strong>and</strong> his family, research means hope<br />

for a cure. Bob feels donations to research<br />

will have long-term benefits for people living<br />

with MS. “While it may be frustrating not to<br />

see an immediate impact, I think research<br />

fosters hope,” Bob says. “<strong>Research</strong>ers<br />

pursue avenues without knowing a definitive<br />

outcome, but there is outst<strong>and</strong>ing value in<br />

their potential <strong>and</strong> the hope they provide.” ■<br />

Dr. Jiwon Oh <strong>of</strong> Johns Hopkins University is<br />

the recipient <strong>of</strong> the Decker Family endMS<br />

<strong>Research</strong> <strong>and</strong> Training Network Transitional<br />

Career Development Award. Her research uses<br />

advanced MRI techniques to determine how<br />

spinal cord lesions, a common problem in MS,<br />

cause sensorimotor deficits.<br />

“This support is invaluable to young investigators<br />

like me,” says Dr. Oh. “It provides us with<br />

material <strong>and</strong> educational support to pursue<br />

academic goals that will make a contribution to<br />

the field <strong>of</strong> multiple sclerosis.”<br />

The award is supported by a gift <strong>of</strong> $500,000<br />

from the Decker family to the endMS<br />

campaign. ■


Lacey Andreas inspires the movement to end <strong>ms</strong><br />

Lacey<br />

Andreas, A&W<br />

Cruisin’ for a<br />

Cause<br />

inspirational<br />

champion<br />

Lacey Andreas, inspirational champion<br />

for the 2012 A&W Cruisin’ for a Cause<br />

campaign, underst<strong>and</strong>s the unpredictability<br />

<strong>of</strong> multiple sclerosis. “I’ve learned to listen<br />

to my body,” says Lacey, who, as a personal<br />

trainer, uses diet <strong>and</strong> exercise to help manage<br />

her sympto<strong>ms</strong>. Now more than ever, Lacey is<br />

hopeful for a future free <strong>of</strong> MS <strong>and</strong> is passionate<br />

about research that will help improve quality <strong>of</strong><br />

life for people living with the disease.<br />

listening to People Affected<br />

by <strong>ms</strong>: We want to hear from you<br />

The MS Society has launched the<br />

Listening to People Affected by<br />

MS initiative, which ai<strong>ms</strong> to hear from<br />

Canadians affected by MS about their<br />

quality <strong>of</strong> life priorities, needs <strong>and</strong><br />

barriers.<br />

The MS Society <strong>of</strong> Canada’s mission is<br />

to be a leader in finding a cure for MS<br />

<strong>and</strong> enabling those affected by MS to<br />

enhance their quality <strong>of</strong> life. We want<br />

to hear directly from you about the<br />

realities <strong>of</strong> your day-to-day life. What<br />

are your priorities when it comes to<br />

living well with MS? Are there barriers<br />

that prevent you from living a full life?<br />

What supports are most helpful? What<br />

are your biggest worries?<br />

On August 23, more than 750 A&W<br />

restaurants across Canada opened their doors<br />

for the fourth annual Cruisin’ for a Cause<br />

Day. Over the summer, the campaign raised a<br />

record total <strong>of</strong> $1.25 million for research <strong>and</strong><br />

services for people living with MS. Every year<br />

A&W franchisees look forward to engaging<br />

with their community on Cruisin’ for a Cause<br />

Day, when one dollar for every Teen Burger ®<br />

goes to the MS Society.<br />

“Big events like Cruisin’ for a Cause fund<br />

research that will have a real impact on<br />

the lives <strong>of</strong> people with MS down the line,”<br />

Lacey says. “People with MS need this kind<br />

<strong>of</strong> support so they can eventually see a real<br />

difference in their everyday lives.”<br />

You can still donate to the A&W<br />

Cruisin’ for a Cause campaign. Visit<br />

cruisinforacause2012.ca to find out how. ■<br />

Have your voice heard through an anonymous,<br />

nationwide survey, <strong>and</strong> help inform the progra<strong>ms</strong>,<br />

services <strong>and</strong> advocacy decisions that we make as<br />

an organization.<br />

We want to hear from:<br />

• those living with a diagnosis <strong>of</strong> MS;<br />

• those waiting for a diagnosis with respect<br />

to MS;<br />

• close friends or family members <strong>of</strong><br />

people with MS;<br />

• caregivers <strong>of</strong> people with MS.<br />

Visit <strong>ms</strong>listening.ca to take the survey online.<br />

To request a paper copy <strong>of</strong> the survey, call<br />

1-800-268-7582. If you request a paper copy,<br />

you will have the option <strong>of</strong> sharing your responses<br />

verbally through a dedicated toll-free number. ■<br />

<strong>ms</strong> canada Fall/Winter 2012 11


stay in the know. For the<br />

most current information<br />

on ccsVI, visit ccsvi.ca<br />

2012 ecTRI<strong>ms</strong> congress:<br />

Access live coverage<br />

The MS Society <strong>of</strong> Canada has partnered<br />

with the National MS Society in the United<br />

States to connect the MS community<br />

with researchers who attended the 2012<br />

European Committee for <strong>Research</strong> <strong>and</strong><br />

Treatment in Multiple Sclerosis Congress.<br />

Access videos <strong>and</strong> highlights from the<br />

conference, which took place in Lyon, France<br />

in October.<br />

Visit blog.national<strong>ms</strong>society.org for English<br />

coverage or sP-ectri<strong>ms</strong>.blogspot.com for<br />

French coverage.<br />

CANADA<br />

Share your comments:<br />

<strong>ms</strong>canada@<strong>ms</strong>society.ca<br />

Fall 2007<br />

Update your mailing address or subscription<br />

preferences by contacting your division <strong>of</strong>fice.<br />

Division contact information can be found at<br />

<strong>ms</strong>society.ca or call 1-800-268-7582 or email<br />

info@<strong>ms</strong>society.ca. To view this publication<br />

online, visit <strong>ms</strong>society.ca/<strong>ms</strong>canada<br />

FPo<br />

“I’m getting benefit from research now, <strong>and</strong><br />

hopefully our estate can help people down the road.”<br />

~ Marion & Martin, British Columbia<br />

RETURN UNDELIVERABLE<br />

CANADIAN ADDRESSES TO:<br />

Multiple Sclerosis Society <strong>of</strong> Canada<br />

700 – 175 Bloor St. E.<br />

Toronto, ON M4W 3R8<br />

What do you want your<br />

legacy to be?<br />

1-800-268-7582<br />

MSlegacy@<strong>ms</strong>society.ca<br />

MSlegacy.ca<br />

Publications<br />

Mail Agreement<br />

# 40063383

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!